Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era

@inproceedings{Wachtel2014OddsOD,
  title={Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era},
  author={Mitchell Wachtel and Shengping Yang},
  booktitle={Cancer medicine},
  year={2014}
}
Bevacizumab (BZM) and temozolomide (TMZ) have been shown to be beneficial in the treatment of patients with glioblastoma. We sought evidence for the benefit of BZM in the general patient population at large. The Surveillance, Epidemiology, and End Results SEER database was queried for patients diagnosed with glioblastoma between 2000 and 2009, divided into a pre-TMZ era (January 2000-June 2003), a transitional era (July 2003-March 2005), a TMZ era (April 2005-October 2007), and a BZM-TMZ era… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
6 Citations
27 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Survival benefit of temozolomide as treatment for glioblastoma; a population based analysis

  • M. Wachtel, B. Miller
  • United States-Canadian Academy of Pathology…
  • 2012
3 Excerpts

boot: bootstrap R (S-Plus) functions. Computer program. R package version 1.3-7

  • A. Canty, B.Ripley
  • R. Vienna,
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…